

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45

SUPPLEMENTARY METHODS

Human ASXL1 Deficiency Causes Epigenetic Dysfunction, Combined Immunodeficiency and EBV-Associated Hodgkin Lymphoma

Maggie P Fu^{1*}, Mehul Sharma^{2*}, Sarah M Merrill³, Pariya Yousefi², Ryan Tan², Bhavi P Modi², Kate Del Bel², Rebecca J Deyell⁴, Jacob Rozmus⁴, Wingfield Rehmus^{2,5}, Kyla J Hildebrand², Elliot James², Géraldine Blanchard-Rohner^{2,6}, Susan Lin², Kevin E Shopsowitz^{2,7}, Audi Setiadi⁷, Jefferson Terry⁷, Anna F Lee⁷, Britt I Drögemöller^{8,9}, Allison Matthews^{1,10}, Maja Tarailo-Graovac^{1,11}, Laura Sauvé^{2,12}, Hana Mitchell², Julie S Prendiville^{2,5}, Julie L MacIsaac^{1,13}, Kristy Dever^{1,13}, David T S Lin¹, Mandy Meijer^{1,13}, Colin J D Ross⁹, Simon R M Dobson^{2,12}, Suzanne M Vercauteren⁷, Wyeth W Wasserman¹, Clara D M van Karnebeek^{2,14,15}, Margaret L McKinnon^{2,16}, Michael S Kobor^{1,13#}, Stuart E Turvey^{2#}, Catherine M Biggs^{2#}

¹British Columbia Children's Hospital, Centre for Molecular Medicine and Therapeutics, Department of Medical Genetics, University of British Columbia, Vancouver, BC, Canada.

²Department of Pediatrics, British Columbia Children's Hospital, The University of British Columbia, Vancouver, BC, Canada.

³Department of Psychiatry and Human Behavior, The Warren Alpert Medical School at Brown University, Providence, RI, USA.

⁴Division of Pediatric Hematology/Oncology/BMT, Department of Pediatrics, British Columbia Children's Hospital, University of British Columbia, Vancouver, BC, Canada.

⁵Divisions of Pediatric Dermatology, Department of Pediatrics, British Columbia Children's Hospital, University of British Columbia, Vancouver, BC, Canada.

⁶Unit of Immunology and Vaccinology, Division of General Pediatrics, Dept. of Woman, Child, and Adolescent Medicine, Geneva University Hospitals and Faculty of Medicine, University of Geneva, Geneva, Switzerland.

⁷Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada.

⁸Department of Biochemistry and Medical Genetics, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, MB, Canada.

⁹Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, BC, Canada.

¹⁰Department of Paediatrics, University of Toronto, Toronto, Ontario, Canada.

¹¹Alberta Children's Hospital Research Institute, Department of Biochemistry and Molecular Biology and Department of Medical Genetics, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.

¹²Pediatric Infectious Diseases, Department of Pediatrics, British Columbia Children's Hospital, University of British Columbia, Vancouver, BC, Canada.

¹³Edwin S.H. Leong Healthy Aging Program, University of British Columbia, Vancouver, Canada.

¹⁴Departments of Pediatrics and Human Genetics, Emma Center for Personalized Medicine, Amsterdam University Medical Centers, Amsterdam, The Netherlands.

46 ¹⁵Centre for Molecular Medicine and Therapeutics, BC Children's Hospital Research
47 Institute, Vancouver, Canada.

48 ¹⁶Department of Medical Genetics, University of British Columbia, Vancouver, Canada.

49

50

51 *These authors contributed equally.

52 #These authors contributed equally.

53

54

55 **Correspondence to:** Catherine M. Biggs, MD, MSc
56 BC Children's Hospital,
57 4480 Oak St,
58 Vancouver, BC, V5Z 4H4, Canada
59 Phone: 604-875-2118 ext 2
60 Email: cbiggs@bcchr.ca
61

62 **SUPPLEMENTARY METHODS**

63 **Sanger sequencing**

64 Briefly, standard sequencing of genomic DNA from all individuals of the family was
65 performed to confirm genotype segregation with the disease in the family using the
66 following primers: Var1: Forward 5'-GAATGACTGCCTTGCTTTAAGA-3', Reverse 5'-
67 AAAGGTTAGTCCCTAGTGCC-3'; Var2: Forward 5'-TGCCAGATAGCTGTGAAACA-3',
68 Reverse 5'-CACATTTGGAGATGAGAAACGA-3'.

69

70 **Identification of candidate variant**

71 Based on family history and pedigree, once a candidate variant list was generated by
72 the pipeline, variants identified through the de novo, autosomal recessive, and
73 compound heterozygous inheritance models were first assessed. All high-impact,
74 putative loss-of-function (LoF) variants were reviewed. Next, the candidate variant list
75 was screened for variants in genes associated with inborn errors of immunity (IEI),
76 especially those previously linked with vaccine-strain rubella-associated granulomas.
77 Genes associated with DNA repair deficiency disorders as well as telomeropathies were
78 also investigated.

79 In addition, a phenotype-driven approach was also employed to identify relevant
80 variants in genes that may be associated with clinical features (using associated MeSH
81 and HPO terms) presented by the proband, such as multiple skin lesions, necrotizing
82 granulomatous inflammation (postvaccine rubella strain identification), idiopathic chronic
83 macrocytosis, low T-cell count, high B-cell count, mild megablastoid changes, mild
84 dysplastic features, infections, pneumonia, failure to thrive, learning disability, and
85 subtle dysmorphic features.

86

87 **Generation and maintenance of primary patient T-cells and fibroblasts**

88 T-cells were treated with exogenous IL-2 (10 U/mL) and ImmunoCult™ Human
89 CD3/CD28 T Cell Activator (Cat # 10971; Stemcell, Vancouver, BC, Canada) for 12

90 days and maintained at a concentration of 10^6 cells/mL every 2 days. After 12 days,
91 exogenous IL-2 concentration was increased to 1000 U/mL.

92 To grow fibroblasts, patient skin was incubated with complete DMEM composed of 10%
93 heat-inactivated FBS (Gibco-BRL Life Technologies, Grand Island, NY, USA; Life
94 Technologies, Gaithersburg, MD, USA), 2mM L-glutamine (HyClone, Thermo Fisher
95 Scientific, Waltham, MA, USA), 1mM sodium pyruvate (Gibco-BRL Life Technologies),
96 and 1× Antibiotic-Antimycotic (Gibco-BRL Life Technologies, Thermo Fisher) for 3
97 weeks at 37°C or until a confluent monolayer of fibroblasts had formed. Primary
98 fibroblasts were then lifted and frozen at -80°C for future assays.

99

100 **Stable expression of ASXL1 using a lentivirus vector**

101 To generate lentivirus vectors, wild-type *ASXL1* (NM_015338) plasmid (Cat#:
102 RG219354; OriGene Technologies, Rockville, MD, USA) was cloned into a GFP-tagged
103 Lenti vector (Cat#: PS100071; OriGene Technologies) using *Ascl* (Cat#: R0558L) and
104 *MluI*-HF (Cat#: R3198L) (both from New England Biolabs, Ipswich, MA, USA). The
105 plasmid was packaged using third-generation packaging plasmids and transfected into
106 HEK293T cells. Culture medium was collected, centrifuged, filtered, concentrated, and
107 stored at -80°C until use. Expanded T-cells were infected with lentiviral particles and
108 expanded in complete RPMI-1640 (GE Healthcare, Chicago, IL, USA) supplemented
109 with 10% FBS for 9 days.

110

111 **Intracellular flow cytometry in PBMCs, expanded T-cells, and primary fibroblasts**

112 Expanded T-cells were first washed and stained with CD4 BUV563 (Clone: SK3, Cat#
113 612912; BD Biosciences, Franklin Lakes, NJ, USA), CD8 BUV395 (Clone: RPA-T8,
114 Cat# 563796; BD Biosciences), and Fixable Viability Stain 780 (Cat#565388; BD
115 Biosciences) for 15 minutes. Cells were then fixed (fibroblasts were lifted, spun, and
116 fixed) using BD Cytofix (Cat# 554655; BD Biosciences) for 20 minutes at room
117 temperature and permeabilized using Perm III for 30 minutes on ice (Cat# 558050; BD
118 Biosciences). The cells were then stained with either primary antibody for ASXL1 (Cat#
119 MA5-36238; Thermo Fisher Scientific) or mouse IgG1 isotype control for 1 hour at room

120 temperature in 1× Perm/Wash (Cat# 554723; BD Biosciences). Intracellular staining
121 was performed separately for H2AK119ub (Cat# 8240S; Cell Signaling Technology,
122 Danvers, MA, USA) in expanded T-cells. Subsequently, the cells were washed and
123 stained with goat anti-mouse secondary antibody (Alexa Fluor™ 405, Cat#: A-31553;
124 Thermo Fisher Scientific) for 30 minutes at room temperature. ASXL1 expression was
125 then measured using a BD FACSymphony flow cytometer (BD Biosciences) and
126 analyzed using FlowJo software (BD Biosciences).

127 Detection of pSTAT5 was performed similar to the protocol outlined above in expanded
128 T-cells and in primary patient peripheral blood mononuclear cells (PBMCs). After
129 permeabilization, cells were stained with mouse anti-human pSTAT5 (pY694) PE-Cy7
130 (Cat# 560117; BD Biosciences). The following antibodies were used for extracellular
131 staining of PBMCs: CD3 FITC (Clone: UCHT1, Cat# 555332; BD Biosciences), CD4
132 BUV563 (Clone: SK3, Cat# 612912; BD Biosciences), CD8 BUV395 (Clone: RPA-T8,
133 Cat# 563796; BD Biosciences), CD27 BV605 (Clone: L128, Cat#: 562655; BD
134 Biosciences), CD45RA BV421 (Clone: HI100, Cat#: 562885; BD Biosciences).

135

136 **Clinical-grade flow cytometry**

137 Patient clinical immunophenotyping was carried out on whole blood at an accredited
138 clinical flow cytometry laboratory according to standard protocols. Briefly, whole blood
139 was collected and stained using dried antibody reagents (DURAClone tubes; Beckman
140 Coulter, Brea, CA, USA) according to the manufacturer's recommendations. Panels
141 focused on the analysis of T-cell subsets (DURAClone IM T Cell Subsets, Cat#:
142 B53328; Beckman Coulter) and B-cell subsets (DURAClone IM B Cell, Cat#: B53318;
143 Beckman Coulter). Samples used for the B-cell subsets were washed three times prior
144 to staining. Aliquots of 100 µL of fresh blood were added to the dried reagent tubes and
145 incubated in the dark at room temperature for 15 minutes prior to lysis with ImmunoPrep
146 Reagent System (Beckman Coulter). Samples were then fixed with 1.0 mL of 1%
147 paraformaldehyde prior to flow cytometry. All flow data were acquired on a Navios flow
148 cytometer and then analyzed using Kaluza software (Beckman Coulter).

149

150 DNA extraction for DNA methylation array analysis

151 Whole blood was collected in Vacutainer® CPT™ Cell Preparation Tubes (Becton
152 Dickinson, Franklin Lakes, NJ, USA). PBMCs were then isolated by standard Ficoll-
153 Plaque (GE Healthcare) density centrifugation. Buccal swabs were collected with
154 Isohelix Buccal Swabs (Cell Projects Ltd., Kent, UK) and Oragene DNA sample
155 collection kits (DNA Genotek, Kanata, ON, Canada), respectively. Genomic DNA was
156 extracted from whole blood, PBMCs, and expanded T-cells with DNeasy kits (Qiagen,
157 Germantown, MD, USA). Buccal DNA was extracted with Isohelix Buccal DNA Isolation
158 kits (Cell Projects Ltd.). Extracted DNA (750 ng) was subjected to bisulfite conversion
159 with an EZ-96 DNA Methylation kit (Zymo Research, Irvine, CA, USA), and aliquots of
160 160 ng were assayed with Infinium HumanMethylationEPIC BeadChip arrays (Illumina,
161 San Diego, CA, USA).

162

163 Sample selection for pediatric population reference set

164 We gathered all cohorts in whole blood, PBMCs, and dried blood spots (DBSs), and
165 excluded cord blood samples. To ensure consistent data preprocessing and
166 minimization of batch effects, we used only cohorts for which raw IDAT files were
167 available in the database. The methylation data and metadata were then compiled
168 manually. Missing metadata were curated from the GEO data set publications and
169 included variables such as age, sex, tissue, ethnicity, and disease status. For disease
170 status, we used the designation of “healthy control” (HC) for samples collected from
171 individuals without persistent severe health conditions, as described in the cohort
172 metadata and the associated publication. Only cohorts that included age information
173 and had samples in the pediatric age range were retained. After quality control (QC),
174 outlier removal, age matching (6–18 years), and selection for HCs, 725 buccal samples,
175 452 WB samples, 285 PBMC samples remained.

176

177 Epigenetic age analysis

178 The *DNAMAge* function in the `methylock` package was used to estimate all DNAM
179 ages in parallel.¹ Epigenetic age acceleration (EAA) was calculated by fitting regression

180 of epigenetic age (EA) to chronological age (CA) and extracting the residual,
181 representing the component of EA that could not be explained linearly by the CA
182 process, whereas epigenetic age difference (EAD) was defined as the difference
183 between EA and CA.

184

185 **Normalization, QC, and imputation of DNA methylation data**

186 For the analysis of primary tissues, the HC cohorts and patient samples were
187 preprocessed together. All subsequent analyses were performed in R version 4.0.3 (R
188 Foundation for Statistical Computing, Vienna, Austria). The IDAT files were normalized
189 with the *preprocessFunnorm* function in the *minfi* package, which included two types
190 of normalization: Noob (normalized out-of-band) normalization and functional
191 normalization.^{2,3} The two normalization steps utilized the readings from control and out-
192 of-band probes to adjust for dye bias from the two-color channels and probe-type bias
193 from Type I and Type II probes on the arrays, respectively. Samples from the 450k and
194 EPIC microarrays were normalized separately, and then combined by subsetting to the
195 shared probes.

196 QC was performed at both sample and probe levels. Samples with bisulfite conversion
197 rate < 75 or average detection *P*-value > .01 were removed. Three other outlier
198 detection methods—*detectOutlier* from *lumi*,⁴ *outlyx* from *watermelon*,⁵ and Z-test on
199 the first principal component (PC)—were implemented to identify outliers with distinct
200 methylation patterns. Furthermore, sex prediction was performed with the *getSex*
201 function in *minfi*. Samples with mismatches in reported and predicted sex were also
202 removed. Finally, probes in which > 5% of samples had bead count < 3 or an average
203 detection *P*-value > .05 were filtered out.

204 After QC, the missing values were imputed in a probe-wise manner based on the DNAm
205 patterns of other probes with the lowest Euclidean distance. The method was
206 implemented with the *imputeKNN* function in the *impute* package, where *k* = 10.

207

208 **Cell type proportion prediction**

209 Cell type proportion of whole blood and PBMC DNAm data were estimated from the
210 imputed data with the Houseman reference-based prediction method,⁶ as implemented
211 using the *estimateCellCounts2* function from the `FlowSorted.Blood.EPIC` package
212 with the `FlowSorted.BloodExtended.EPIC` reference.⁷ In buccal swabs, cell type
213 proportion was predicted with the *hepidish* function in the `EpiDISH` package⁸. We
214 compared the estimated proportion of each cell type between the patient and HCs using
215 the one-sample *t* test.

216

217 **Correcting for variances associated with intersample cellular heterogeneity**

218 Given that the patient shows unique cell type proportions distinct from the HC, it is
219 essential to adjust for cell type-associated DNAm variation to prevent confounding with
220 the disease-associated DNAm signature. In the primary tissues, this was accounted for
221 with a regression model. To overcome the compositional nature of cell type proportion
222 data, we first transformed the proportion into an isometric log ratio followed by principal
223 component analysis (PCA) to extract components that capture the variabilities
224 corresponding to cell type differences, yet are not bounded or correlated. We then fitted
225 a regression model of the DNAm beta value as a function of the cell type PCs⁹ and
226 extracted the residuals as the cell type-adjusted DNAm values. For the analysis in T-
227 cells, we accounted for the CD8 proportion directly as a covariate in our EWAS.

228

229 **Batch correction**

230 Given that we only included samples for which raw IDAT files were available, we also
231 had access to the chip ID and position at which each sample was run. We identified
232 three known sources of batch effect, ie, the array platform (450k or EPIC), chip ID, and
233 chip row. Therefore, we adjusted the data for these three known batch effects with the
234 *ComBat* function in the `sva` package,¹⁰ which uses an empirical Bayesian framework to
235 estimate the batch effect on samples across probes and account for them with a
236 regression model. Each cohort can also be considered as a batch, but that is often
237 confounded with different tissues, disease status, and age range, so we did not include

238 cohort as a known batch variable. We confirmed that the batch effect of the three
239 variables were removed with PCA. Platform ID, chip ID, and chip row were originally
240 strongly correlated with PC1 through PC5 on Pearson's correlation test (multiple test
241 adjusted $P < .001$), and most of the effects were removed by *ComBat*. For the T-cell
242 DNAm data, we accounted for batch in the `limma` regression model, as too few batches
243 were present, and we did not detect a strong batch effect within each time point.

244

245 **Differential DNAm analysis of expanded T-cells**

246 The expanded T-cells for the DNAm arrays were collected over 3 days to capture some
247 biological and technical variability. In the linear regression model, we accounted for
248 concomitant variables in our analysis, including sex, age, and technical batch, to
249 specifically isolate the effect of patient *ASXL1* genotype. We identified 276 769
250 differentially methylated sites (DMs) with a statistical cutoff with $P_{adj} \leq .05$ and effect size
251 (ES) cutoff with $\Delta\beta > 0.1$. The same regression model comparing *rescue vs.*
252 *control* yielded 208,692 DMs passing the statistical and ES thresholds. We then
253 included flow-derived CD8⁺ proportion with other concomitant variables in the model to
254 account for cellular heterogeneity. With the new model, we no longer observed any DMs
255 passing the statistical threshold of $P_{adj} < .05$, showing that *ASXL1* variants led to an
256 imbalance in CD4⁺ and CD8⁺ T-cell proportions, and that *ASXL1* has a strong cell
257 population-specific effect on DNAm pattern. We relaxed the statistical threshold to $P_{adj} <$
258 $.2$ and detected 141,113 DMs. Downstream analysis are performed with this model and
259 detection threshold.

260

261 **Enrichment analysis for differential DNA methylation**

262 Overrepresentation analyses were conducted using the *gometh* function in the
263 `missMethyl` package to identify enriched ChromHMM chromatin states. The
264 ChromHMM states were exported from the Roadmap Epigenomics database and
265 overlapped with the Illumina annotation file for the EPIC arrays.¹¹ The method accounts
266 for the background probes on the DNAm arrays to minimize coverage biases. The
267 probes were annotated to the corresponding genes and the enriched pathways with
268 multiple test-adjusted $P < .05$ were identified.

269 Supplementary Clinical Data**270 Presentation and treatment of EBV-associated Hodgkin lymphoma**

271 Between 10 to 15 years of age the patient presented with a three-month history of
272 epistaxis and gum bleeding. Mildly reduced platelets with elevated mean platelet
273 volume, suggestive of peripheral destruction, prompted an abdominal ultrasound which
274 identified hepatosplenomegaly. A chest CT demonstrated diffuse intrathoracic
275 lymphadenopathy and baseline positron emission tomography (PET)-CT revealed ¹⁸F-
276 fluorodeoxyglucose (FDG)-avid disease above and below the diaphragm, pulmonary
277 nodules, hepatic and splenic lesions with innumerable marrow deposits. An axillary
278 lymph node biopsy confirmed the diagnosis of stage IVA classical Hodgkin lymphoma,
279 mixed cellularity subtype with prominent granulomatous inflammation (**Supp Fig 1D**).
280 She had an associated EBV viremia (EBV viral load 15,529 copies/ml) and
281 immunohistochemistry of Reed-Sternberg cells from her diagnostic lymph node biopsy
282 were positive for EBV-encoded RNA (EBER). Bone marrow aspirate and biopsy showed
283 numerous lymphohistiocytic aggregates, in addition to mild megakaryocytic atypia and
284 mild red blood cell macrocytosis.

285

286 She received 2 cycles of ABVD (doxorubicin [adriamycin], bleomycin, vinblastine and
287 dacarbazine) chemotherapy with a partial metabolic response (Deauville 4), and was
288 then switched to AVD with brentuximab-vedotin, the anti-CD30 antibody, for cycles 3
289 and 4 due to significant myelosuppression and slow early response. Repeat PET-CT
290 done after 4 cycles of chemotherapy showed progressive disease with 2 new FDG-avid
291 lesions (spleen and right humerus). The splenic lesion was biopsied and histology
292 remained in keeping with classical Hodgkin lymphoma. Following tumour board review,
293 she initiated immunotherapy with nivolumab, the anti-programmed cell death protein 1
294 (PD1) antibody. This was complicated by the development of autoimmune thyroiditis,
295 which was treated with thyroxine. She completed 4 cycles of nivolumab after which
296 PET-CT re-evaluation was indeterminate with persistent FDG-avid lesions potentially
297 related to her chronic skin lesions and an intercurrent axillary seroma, but no definitive
298 disease progression. Six weeks following discontinuation of nivolumab, she began
299 conditioning for a 9/10 matched unrelated donor hematopoietic stem cell transplant with

300 cyclophosphamide, fludarabine and 200cGy total body irradiation. She received
301 mycophenolate mofetil and tacrolimus prophylaxis for graft versus host disease (GVHD)
302 and developed grade 1 GVHD of upper gut and skin which was treated with
303 corticosteroids. She was discharged on day +34 with full donor chimerism, and remains
304 well now 6 months post-transplant with healing of her chronic skin lesions.

305 **SUPPLEMENTARY REFERENCES**

306

- 307 1. Pelegi-Siso D, de Prado P, Ronkainen J, Bustamante M, Gonzalez JR.
308 methylclock: a Bioconductor package to estimate DNA methylation age. *Bioinformatics*
309 2021;37:1759-60.
- 310 2. Fortin JP, Labbe A, Lemire M, et al. Functional normalization of 450k methylation
311 array data improves replication in large cancer studies. *Genome Biol* 2014;15:503.
- 312 3. Fortin JP, Triche TJ, Jr., Hansen KD. Preprocessing, normalization and
313 integration of the Illumina HumanMethylationEPIC array with minfi. *Bioinformatics*
314 2017;33:558-60.
- 315 4. Du P, Kibbe WA, Lin SM. lumi: a pipeline for processing Illumina microarray.
316 *Bioinformatics* 2008;24:1547-8.
- 317 5. Pidsley R, CC YW, Volta M, Lunnon K, Mill J, Schalkwyk LC. A data-driven
318 approach to preprocessing Illumina 450K methylation array data. *BMC Genomics*
319 2013;14:293.
- 320 6. Houseman EA, Accomando WP, Koestler DC, et al. DNA methylation arrays as
321 surrogate measures of cell mixture distribution. *BMC Bioinformatics* 2012;13:86.
- 322 7. Salas LA, Zhang Z, Koestler DC, et al. Enhanced cell deconvolution of peripheral
323 blood using DNA methylation for high-resolution immune profiling. *Nat Commun*
324 2022;13:761.
- 325 8. Zheng SC, Webster AP, Dong D, et al. A novel cell-type deconvolution algorithm
326 reveals substantial contamination by immune cells in saliva, buccal and cervix.
327 *Epigenomics* 2018;10:925-40.
- 328 9. Jones MJ, Islam SA, Edgar RD, Kobor MS. Adjusting for cell type composition in
329 DNA methylation data using a regression-based approach. *Methods in Molecular*
330 *Biology* 2017:99-106.
- 331 10. Leek JT, Johnson WE, Parker HS. The sva package for removing batch effects
332 and other unwanted variation in high-throughput experiments. *Bioinformatics*
333 2012;28:882-3.
- 334 11. Roadmap Epigenomics C, Kundaje A, Meuleman W, et al. Integrative analysis of
335 111 reference human epigenomes. *Nature* 2015;518:317-30.
- 336 12. Gatev E, Gladish N, Mostafavi S, Kobor MS. CoMeBack: DNA methylation array
337 data analysis for co-methylated regions. *Bioinformatics* 2020;36:2675-83.
- 338 13. Awamleh Z, Chater-Diehl E, Choufani S, et al. DNA methylation signature
339 associated with Bohring-Opitz syndrome: a new tool for functional classification of
340 variants in ASXL genes. *Eur J Hum Genet* 2022;30:695-702.

341

342

343

344 **Supplementary Figure Legends:**

345

346 **Supp. Figure 1:** A) White blood cell count assessment over time showed normal white
347 blood cell count. B) Immunoglobulin assessment over time showed low IgG until
348 initiation of intravenous immunoglobulin (IVIG), low/normal IgM levels and low/normal
349 IgA levels. C) Skin biopsy performed in childhood (0-10 years of age) from the left thigh.
350 Tissue section stained with hematoxylin and eosin showing subcutaneous necrotizing
351 (*) and nonnecrotizing granulomas (arrowhead). Specific staining for organisms was
352 negative (not shown). Scale bar: 200 μ m. D) Micrograph of lymph node indicating
353 juxtaposed granulomatous inflammation (*) and classical Hodgkin lymphoma with
354 Reed–Sternberg cells (arrowheads). Scale bar: 200 μ m.

355

356 **Supp. Fig. 2:** A) Predicted CADD score (v1.6) and allelic frequency of ASXL1 variants
357 reported in the gnomAD database (v3). All missense (gray), stop-gained (navy blue), or
358 frameshift (magenta) variants are plotted. Patient variants are indicated with a triangle.

359

360 **Supp. Fig. 3:** A) Volcano plot of differential DNAm pattern detected in buccal swabs
361 with linear regression. Delta beta represented the effect size (regression coefficient) of
362 the patient status variable after accounting for sample age and sex. Magenta points
363 indicate DMs with increased DNAm in the patient, and turquoise points represent those
364 with decreased DNAm. The vertical gray line represents the delta-beta = 0.05, and the
365 horizontal line corresponds to $P_{adj} = 0.05$. B) Overlap of differentially methylated CpGs
366 identified in our whole blood analysis and those associated with Bohring–Opitz
367 syndrome in a previous study¹³. C) CA and predicted PedBE EA in the patient and HCs.
368 HC samples are shown in light blue, while patient samples are shown in red. The black
369 line indicates the best fit line using linear regression of all the sample points. The gray
370 area corresponds to the 95% confidence interval. D) Telomere length of patient
371 lymphocytes and granulocytes compared with the reference range in the HC population.

372

373 **Supp. Fig. 4:** A,B) Epigenetic age analysis in expanded T-cells, ($n = 3$ for patient and
374 rescued samples). A) Difference in Horvath skin and blood epigenetic age and

375 chronological age. B) Difference in Hannum epigenetic age and chronological age. 0.05,
376 ** $P < .01$, *** $P < .001$, one-way analysis of variance with Dunnett's multiple comparison
377 test.

378

379 **Supp. Fig. 5: Extended T-cell phenotyping of the index patient.** pSTAT5 response
380 in the A) memory CD4 T and B) memory CD8 T-cell subsets of patient and control
381 PBMCs after stimulation with 1, 10, or 100 U/mL IL-2. Patient (purple), family controls
382 (orange), HCs (light blue). Two different time points of patient samples are presented
383 with different symbols (triangles and circles). C) Oxidative stress was detected in
384 expanded CD4⁺ and CD8⁺ T-cells of the patient and controls (family and HC) by flow
385 cytometry using CellROX Deep Red reagent. * $P < .05$, ** $P < .01$, one-way analysis of
386 variance and Tukey's post hoc test.

387